Dermal Fillers: Types, Duration, Reversibility and Risks

Dermal fillers: types, duration, reversibility, and risks

Dermal fillers are implants injected into soft tissue to create a smoother or fuller appearance. Specific products may be used for particular indications in the lips, cheeks, chin, facial folds, or backs of the hands, depending on the product and country.

The word “filler” is sometimes used to group hyaluronic acid, biostimulators, polynucleotides, mesotherapy, and autologous fat. That marketing category can be confusing: these are not the same material, do not have the same regulatory status, and do not share indications, duration, technique, or complication management.

For the options available at the clinic, see information about facial harmonization treatment at Juvenalia Brío.

What are dermal fillers?

The U.S. FDA describes fillers as soft-tissue implants. Some produce immediate volume; others create gradual change. Composition and behavior matter more than broad labels such as “filler,” “biostimulator,” or “bioremodeler.”

Not every injectable promoted for “skin quality” is an approved filler. PDRN, polynucleotides, Profhilo, skinboosters, mesotherapy cocktails, and hybrid products must be assessed by exact name, manufacturer, indication, and instructions for use. One promise of hydration, regeneration, or collagen production cannot be assigned to the entire group.

Main materials

Polycaprolactone, hybrids, and other materials may be available in some jurisdictions but should not be described as approved in Mexico or the United States without checking the exact product and indication.

Where can fillers be injected?

Authorized areas vary by product. In the United States, the FDA has approved specific products for certain uses in adults, including some facial folds and wrinkles, lips, cheeks, chin, and the backs of the hands. Specific products also exist for certain infraorbital indications.

This does not mean every filler is approved for all those areas. The nose, glabella, forehead, eye region, and neck include uses that the FDA does not authorize generally for fillers. In Mexico, the local indication for every presentation must be checked.

A “material by area” chart is misleading because safety depends on:

• local anatomy and blood vessels;
• product, concentration, and physical properties;
• injection plane and technique;
• amount required;
• the person’s history and goals;
• the injector’s training and ability to recognize and treat complications.

Injectable fillers for buttock augmentation or body contouring should not be presented as routine. The FDA recommends against using fillers to enlarge the buttocks, breasts, feet, or other unauthorized body sites.

Filler, biostimulator, and “bioremodeler”

These terms describe broad goals or mechanisms, not a universal regulatory taxonomy.

• A volumizing filler aims to provide visible support or volume.
• A product called a biostimulator generally creates gradual change associated with tissue response.
• A “bioremodeler” or “skin-quality injectable” can refer to very different products and does not guarantee no volume, preventive benefit, or clinically meaningful collagen production.

“More natural,” “safer,” or “longer-lasting” does not follow from the category. It must be supported by the exact product’s labeling and evidence.

One example: Sculptra

Sculptra contains poly-L-lactic acid. An April 25, 2023 FDA approval expanded its use to correction of fine lines and wrinkles in the cheek region of immunocompetent adults. The study for that indication allowed up to four treatments, and results could last up to 24 months.

This does not establish a universal protocol of two or three sessions four to six weeks apart, and “up to 24 months” is not a guarantee. Sculptra also has a regulatory history involving other specific indications; they should not be blended into one statement. Its current Mexican indication must be checked in the local registration and instructions.

How long do fillers last?

Duration depends on the exact product, treatment site, volume, technique, and individual response. Even one brand can contain formulations with different outcomes.

Use the local instructions as an estimate, not a promise. “Hyaluronic acid lasts 6–18 months,” “CaHA lasts 12–18 months,” or “PCL lasts more than two years” are too general to select a treatment.

Temporary products may require further treatment to maintain an effect. Repeating treatment before the result disappears does not guarantee that every session will last longer.

Are fillers reversible?

Hyaluronic acid

Hyaluronidase can reduce or dissolve many HA fillers. However:

• more than one session may be needed;
• speed and completeness vary;
• allergic reactions can occur;
• tissue may not return exactly to its prior appearance;
• it does not replace emergency treatment for vascular occlusion.

Having hyaluronidase available is preparedness, not insurance against necrosis, blindness, or stroke.

Other materials

CaHA, PLLA, PCL, and PMMA are not removed with hyaluronidase. The FDA says reducing or removing filler may require injections, surgery, or other interventions and can sometimes be difficult or impossible.

Risks and side effects

Common effects include redness, swelling, pain, tenderness, bruising, and itching. They may last days or weeks. Nodules, granulomas, infection, open wounds, migration, allergic reactions, and inflammation can also appear weeks, months, or years later.

Vascular occlusion

The most concerning complication is accidental entry into a blood vessel, blocking blood flow. This can cause tissue death, visual impairment, blindness, stroke, and even death.

Get immediate medical care if during or after injection you notice:

• severe or unusual pain;
• blurred, changed, or lost vision;
• white, gray, blue, or net-like skin discoloration;
• weakness or numbness on one side;
• trouble speaking, confusion, severe dizziness, or a sudden severe headache.

Do not wait for a follow-up appointment or massage the area yourself.

Who should postpone or seek advice first?

Tell the clinician if you have:

• inflammation, pimples, hives, a wound, or active infection in the area;
• a history of herpes;
• a bleeding disorder or anticoagulant use;
• severe allergies or anaphylaxis;
• a tendency to keloid or hypertrophic scars;
• autoimmune disease or immune suppression;
• recent dental procedures, vaccination, or infection;
• pregnancy or breastfeeding.

The FDA says safety during pregnancy and breastfeeding has not been established for the fillers it regulates. The decision should not be based on the material being “naturally present” in the body.

Do not stop prescribed anticoagulants, antiplatelet medicines, or other medication unless the prescribing clinician tells you to.

Before treatment

Ask:

1. What is the full product name and manufacturer?
2. Is its COFEPRIS registration current, and what indication does it cover?
3. Can I see the sealed box and syringe, lot, and expiration?
4. What experience does the injector have with this area?
5. Which risks are specific to this anatomy?
6. What is the plan for vascular occlusion or a severe reaction?
7. What result and duration are reasonable according to the product instructions?
8. What alternatives exist, including no treatment?

Do not buy the product yourself. The FDA warns against fillers sold directly to the public and needle-free injection devices.

After treatment

Follow the product-specific and clinician instructions. Swelling and bruising can distort the initial result, so it should not be judged immediately.

Advice about exercise, sun, makeup, massage, and other procedures varies. The AAD generally advises waiting until the next day for strenuous exercise, avoiding sun and tanning, and not touching the area unless instructed. Some products, such as PLLA, have specific massage directions that should not be applied to every filler.

Regulation: Mexico, United States, and Europe

Mexico

COFEPRIS publishes medical-device registration lists. Verification must use the exact name and presentation, not only the brand. A distributor, attractive packaging, or foreign approval does not prove a current Mexican registration.

United States

The FDA approves exact fillers for exact uses. Its approved-product page and each label specify treatment area, age, material, and evidence. U.S. approval is context, not authorization for use in Mexico.

European Union

It is inaccurate to say “EMA approves fillers.” Manufacturers place a CE mark after conformity assessment, usually conducted by a notified body designated by an EU member state. EMA has limited consultative roles for certain device categories.